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Analysis of postmarketing safety 
data for proton-pump inhibitors 
reveals increased propensity 
for renal injury, electrolyte 
abnormalities, and nephrolithiasis
tigran Makunts, Isaac V. Cohen, Linda Awdishu  & Ruben Abagyan
proton pump inhibitors, ppIs, are widely prescribed and sold globally. Although initially intended 
for time-limited treatment of acute disorders, such as gastric ulcers and esophagitis, ppIs are now 
commonly used for prolonged durations and are considered safe for over the counter access. Recent 
studies have raised concern over associations between ppI use and acute kidney injury, chronic kidney 
disease, end-stage renal disease, and electrolyte abnormalities. the growing concern over potentially 
serious adverse drug reactions warrants an evaluation of post marketing surveillance data. In this study 
of over ten million FDA Adverse event Reporting system records, we provided evidence of kidney injury 
and electrolyte imbalances in an alarming number of patients taking ppIs. Additionally, we assessed 
differences between specific PPIs and observed significant electrolyte and renal abnormalities for each 
individual drug with varying magnitudes.
The World Health Organization includes proton pump inhibitors (PPIs) in the list of essential medicines and 
health products1. PPIs have demonstrated superior efficacy to histamine-2 receptor antagonists (H2RAs) in 
treatment of acid-related disorders and have replaced the H2RAs2,3. The current indications include treatment 
of gastroesophageal reflux disease, non-steroidal anti-inflammatory drug (NSAID) and Helicobacter pylori 
induced ulcers, duodenal ulcers, erosive esophagitis, and other pathological hypersecretory conditions, including 
Zollinger-Ellison syndrome4,5 (see Supplement-Appendix A for a more comprehensive indication list reported to 
FDA) and are now one of the most widely utilized medications6. The superior efficacy is credited to the mecha-
nism of action. All currently marketed PPIs inhibit the hydrogen pump H +/K+ ATPase irreversibly, preventing 
the last and rate-limiting step in acid secretion by parietal cells in the stomach7,8. There are currently six Food 
and Drug Administration (FDA) approved PPIs: rabeprazole, lansoprazole, pantoprazole, esomeprazole, ome-
prazole, and dexlansoprazole. These were sequentially developed due to varying pharmacokinetic parameters, 
such as extended plasma half-life, routes of administration, and drug interactions9,10. The most common PPI 
adverse reactions (ADRs) are mild and include headache, nausea, stomach pain, diarrhea, vomiting, and flatu-
lence. Serious allergic reactions include rash, facial swelling, throat tightness, and difficulty breathing11. Generally 
considered safe, PPIs are now commonly used for prophylaxis and sold over the counter in most of the indus-
trialized countries, including the United States, with annual prescription and over the counter sales exceeding 
fourteen billion dollars anually12.
Recently, PPI use has come under scrutiny due to growing evidence of renal, cardiovascular, autoimmune 
and neurologic adverse effects. New data has revealed associations with myocardial infarction13, Clostridium 
difficile-associated diarrhea14, community acquired pneumonia15, bone fractures16, subacute cutaneous lupus ery-
thematosus17,18, Alzheimer’s dementia19,20, and kidney injury21–29. Here we evaluated the frequencies of reported 
adverse events related to kidney injury and electrolyte disturbances in patients taking PPIs. We also compared the 
magnitude of the effects for individual PPIs.
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Results
ppI “monotherapy”-related renal and electrolyte ADRs. Patients who used PPIs with no other 
reported concurrent medications had a significant increase in the frequency of the following renal adverse event 
reports compared to the H2RAs: chronic kidney disease (CKD) (OR 28.4, 95% CI [12.7, 63.5]), acute kidney 
injury (AKI) (4.2 [2.8, 6.3]), end-stage renal disease (ESRD) (35.5 [5.0, 250.0]), renal impairment of unspecified 
type (8.0 [5.0, 13.0]), and nephrolithiasis (2.8 [1.3, 6]) (Fig. 1b). The composite renal ADR frequency was 5.6% of 
the total PPI “monotherapy” ADRs reports and 0.7% for H2RA “monotherapy” reports (8.6 [6.6, 11]) (Fig. 1a).
Interestingly, relative frequencies for electrolyte abnormalities followed the same trend (Fig. 2a) and were also 
increased for PPI users: hypomagnesemia (OR 78.5 [11, 560]), hypocalcemia (25.5 [6.4, 100]), hypokalemia (6.3 
[2.6, 15]), and hyponatremia (2.2 [1.1, 4.6]) (Fig. 2b).
Renal impairment and Individual ppIs. Analysis of renal and electrolyte adverse effects for each individ-
ual PPI produced the following results shown in Fig. 3.
Acute Kidney Injury. Patients who received the following PPIs as “monotherapy” had a significant increase 
in the frequency of AKI reports: omeprazole (OR 5.8 [3.8, 8.9]), esomeprazole (3.3 [2.2, 5]), pantoprazole (1.8 
[1.01, 3.3]), and lansoprazole (10.8 [7.0, 17]). Patients who received rabeprazole as “monotherapy” had an 
increase in AKI frequency, but it was not significant (1.8 [0.6, 5.3]) (Fig. 3a).
Chronic Kidney Disease. Patients who received the following PPIs as “monotherapy” had a significant 
increase in the frequency of CKD reports: omeprazole (OR 18.1 [7.9, 41]), esomeprazole (29.9 [13, 67]), and 
lansoprazole (154.9 [49, 490]). Patients who received rabeprazole and pantoprazole as “monotherapy” had an 
increase in CKD frequency, but the significance criteria were not met (1.9 [0.2,16]) and (3.0 [0.7, 14]) respectively 
(Fig. 3b).
end stage Renal Disease. ESRD is of particular concern due to the limited prognosis in the absence of 
receiving dialysis or a kidney transplant. Very large OR values were determined for three widely used PPIs: ome-
prazole (OR 30.1 [4.1, 220]), esomeprazole (34.7 [4.8, 250]), and lansoprazole (97.6 [13, 710]) demonstrating 
a significant association with ESRD. The frequency of ESRD with pantoprazole “monotherapy” did not reach 
statistical significance (4.6 [0.4, 50]). Patients who received rabeprazole did not have any ESRD reports (Fig. 3c).
Nephrolithiasis. Within the PPI cohort, patients who received the following PPIs as “monotherapy” had a 
significant increase in the frequency of nephrolithiasis reports: omeprazole (OR 3.4 [1.4, 7.9]), esomeprazole (2.4 
[1.1, 5.3]), pantoprazole (3.3 [1.2, 8.6]), and lansoprazole (3.9 [1.5, 10.1]). Patients who received rabeprazole as 
“monotherapy” according to FAERS reports had an increase in nephrolithiasis frequency but did not meet the 
significance criteria (3.3 [0.7, 15.8]) (Fig. 3d).
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Figure 1. Frequencies and odds ratios (ORs) of renal adverse drug reactions (ADRs). (a) Frequencies of renal 
adverse events for patients in FAERS/AERS who took PPIs (n = 42,537) and H2RAs (n = 8,309). (b) Odds ratios 
were calculated comparing adverse event frequencies of PPI and H2RA patients. Abbreviations: CKD-Chronic 
Kidney Disease, AKI-Acute Kidney Injury, ESRD-End Stage Renal Disease, and NOS-Not otherwise specified. 
Ranges represent 95% confidence intervals (95% CI) (see Methods). X-axis is presented in log scale.
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Figure 2. Frequencies and ORs of electrolyte related ADRs. (a) Frequencies of electrolyte related events for 
patients on PPIs (n = 42,537) and H2RAs (n = 8,309). (b) Odds ratios were calculated from adverse event 
frequencies. Ranges represent 95% confidence intervals (see Methods). X-axis is presented in log scale.
Figure 3. Renal ADR ORs of individual PPIs used as “monotherapy” (Rabeprazole n = 724, Lansoprazole 
n = 3,360, Pantoprazole n = 3,651, Esomeprazole n = 27,053, Omeprazole n = 7,749) when compared to H2RAs 
(n = 8,309). Odds ratios were calculated comparing (a) AKI (b) CKD, (c) ESRD (d) Nephrolithiasis and (e) 
renal impairment adverse event report frequencies of individual PPIs to all H2RAs (x-axis presented in log 
scale). NOS = not otherwise specified.
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Renal Impairment. A large portion of renal impairment reports did not specify acuity of the injury, marked 
as renal impairment NOS (not otherwise specified). It was important to see if the observed renal side effects of 
PPIs persisted in this category of reports. In agreement with the preceding results, the OR values were signif-
icantly increased: omeprazole (OR 11.5 [7.1, 19]), esomeprazole (7.9 [4.9, 13]), pantoprazole (2.9 [1.6, 5.4]), 
lansoprazole (5.0 [2.8, 8.8]) and rabeprazole (12.4 [6.5, 24]) (Fig. 3e).
electrolyte Disturbances: magnesium, calcium, potassium, sodium. All five PPIs were associated 
with a dramatic increase in hypomagnesemia reports (Fig. 4a, Table 1). Additionally, all the studied PPIs were 
associated with a significant increase in hypocalcemia reports (Fig. 4b, Table 1). Patients who received the fol-
lowing PPIs had an increase in the frequency of hypokalemia reports: omeprazole, esomeprazole, pantoprazole, 
and lansoprazole. Patients who received rabeprazole had an increase in hypokalemia frequency, but it was not 
statistically significant (Fig. 4c, Table 1).
Hyponatremia was the least pronounced, yet still significant, electrolyte disturbance associated with omepra-
zole, lansoprazole, and rabeprazole. In contrast, reports of hyponatremia with esomeprazole or pantoprazole did 
not reach statistical significance. (Fig. 4d, Table 1).
Methods
FDA Adverse event Reporting system. The FDA Adverse Event Reporting System (FAERS) supports 
FDA’s post marketing surveillance on drugs and biologic therapeutics submitted to FDA through MedWatch, the 
FDA Safety Information and Adverse Event Reporting Program. Reporting is voluntary and is done by doctors, 
pharmacists, legal representatives, other healthcare providers and patients. The manufacturer is the only contrib-
utor that is legally required to forward the information to the FDA.
Over 10.3 million FAERS/AERS reports, from January 2004 to March 2018, were used for the analysis. 
Data sets are available online at: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Surveillance/AdverseDrugEffects/ucm082193.htm.
Normalizing and combining the FAeRs/AeRs reports. Throughout the data set, the quarterly online 
reports were not homologous from year to year. Each quarterly set was downloaded in dollar-separated text for-
mat (.txt) and modified, standardized, and extended. Missing columns in data sets were added with no values and 
the column names were homogenized. The final data set version contained over 10.3 million reports. Most of the 
reports were submitted from the United States, and many were submitted from all around the world with their 
respective country specific demographic formats. Online drug databases were used to generate a dictionary with 
all international brand/generic drug names and to translate them into generic names.
study outcomes. A fraction of the observed 20,317 outcomes in FAERS and AERS were grouped into the 
following generalized outcomes for a priori hypothesis: chronic kidney disease (CKD: defined in FAERS and 
AERS data sets as chronic kidney disease, and chronic renal failure), acute kidney injury (AKI: acute kidney 
injury, acute prerenal failure, renal failure acute), and end-stage renal disease (ESRD: end stage renal disease, end 
stage kidney disease), nephrolithiasis, renal impairment NOS (renal failure, renal impairment, renal disorder, 
renal injury), hypomagnesemia (hypomagnesemia, decreased blood magnesium), hypocalcemia (hypocalcemia, 
Figure 4. Electrolyte ADR odds ratios of individual PPIs used as “monotherapy” (Rabeprazole n = 724, 
Lansoprazole n = 3,360, Pantoprazole n = 3,651, Esomeprazole n = 27,053, Omeprazole n = 7,749) when 
compared to all H2RAs (n = 8,309). Odds ratios were calculated comparing (a) hypomagnesemia, (b) 
hypocalcemia, (c) hypokalemia, and (d) hyponatremia adverse event report frequencies of individual PPIs to all 
H2RAs.
www.nature.com/scientificreports/
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decreased blood calcium), hypokalemia (hypokalemia, decreased blood potassium) and hyponatremia (hypona-
tremia, decreased blood sodium).
Choice of cohorts. A total of 10,324,033 FAERS and AERS reports were collected. Reports where omepra-
zole, esomeprazole, rabeprazole, lansoprazole, pantoprazole, and dexlansoprazole were used, excluding reports 
with concurrent use of any H2RAs, were selected into the PPI cohort (n = 732,696). Reports where ranitidine, 
famotidine, cimetidine, and nizatidine were used, excluding reports with concurrent use of any PPI, were selected 
into the H2RA cohort (n = 162,189). Further, reports where PPIs and H2RAs were used as monotherapy were 
selected into the respective cohorts. The term “monotherapy” pertains to records where PPIs and H2RAs were 
the only reported medications. PPIs-only cohort comprised of 42,537 reports and H2RA-only cohort comprised 
of 8,309 reports.
Odds ratio analysis was performed by comparing the ADR frequencies of PPIs in relation to H2RA “mono-
therapy” frequencies. The PPI “monotherapy” cohort was further split into individual PPI cohorts which included 
omeprazole (n = 7,749) esomeprazole (n = 27,053), pantoprazole (n = 3,651), lansoprazole (n = 3,360), and rab-
eprazole (n = 724). There were no reports where dexlansoprazole was used as “monotherapy”. Reports with two 
or more PPIs used were excluded (Fig. 5). Demographic analysis was performed (Tables 2 and 3). Overall dis-
tributions strongly overlap and validate the cohort choice. Each individual PPI cohort frequency of renal and 
electrolyte ADRs was calculated and compared to the H2RA cohort to screen for potential ADR variability within 
individual PPIs in the cohort (Figs 3 and 4).
statistical analysis. Descriptive Statistics. Frequencies for each studied side effect (Figs 1a and 2a) was 
calculated by the equation:
= ⁎Frequency Number of Records with ADR Number of Patient Records( )/( ) 100 (1)
Comparative Statistics. ADR report rates were compared via the Odds Ratio (OR) analysis for Figs 1b, 2b, 3 and 
4 using the following equations:
=OR a b c d( / )/( / ) (2)
where
a: Number of cases in exposed group with an adverse event.
b: Number of cases in exposed group with no adverse event.
c: Number of cases in control group with the adverse event.
d: Number of cases in control group with no adverse event.
ADR PPIs OR 95% CI lower 95% CI upper
Hypomagnesemia
Omeprazole 224.6 31.0 1600.0
Esomeprazole 30.2 4.2 220.0
Pantoprazole 115.4 16.0 840.0
Lansoprazole 82.4 11.0 600.0
Rabeprazole 151.9 20.0 1200.0
Hypocalcemia
Omeprazole 75.3 19.0 300.0
Esomeprazole 10.0 2.4 41.0
Pantoprazole 21.7 5.1 93.0
Lansoprazole 41.2 9.9 170.0
Rabeprazole 28.9 5.6 150.0
Hypokalemia
Omeprazole 15.8 6.3 39.0
Esomeprazole 3.1 1.2 7.7
Pantoprazole 6.4 2.3 18.0
Lansoprazole 11.0 4.1 29.0
Rabeprazole 2.3 0.3 20.0
Hyponatremia
Omeprazole 7.0 3.3 15.0
Esomeprazole 0.6 0.3 1.4
Pantoprazole 2.0 0.7 5.5
Lansoprazole 4.0 1.7 9.7
Rabeprazole 4.3 1.1 16.0
Table 1. Electrolyte ADR odds ratios and 95% CIs of individual PPIs used as “monotherapy” (Rabeprazole 
n = 724, Lansoprazole n = 3,360, Pantoprazole n = 3,651, Esomeprazole n = 27,053, Omeprazole n = 7,749) 
when compared to all H2RAs (n = 8,309). Odds ratios were calculated comparing hypomagnesemia, 
hypocalcemia, hypokalemia, and hyponatremia adverse event report frequencies of individual PPIs to all 
H2RAs.
www.nature.com/scientificreports/
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=LnOR Ln(OR) (3)
= + + +Standard Error of Log Odds Ratio SE LnOR a b c d; ( ) (1/ 1/ 1/ 1/ ) (4)
95% Confidence Interval;
= − . × + . ×CI exp LnOR SE to exp LnOR SE95% ( 1 96 ) ( 1 96 ) (5)LnOR LnOR
Figure 5. Legend: Inclusion exclusion and analysis cohort selection for adverse event rate comparison between 
PPIs and H2Ras as a class, as part of therapeutics, “monotherapy”, and between individual PPIs and all H2RAs.
Country No. of PPI reports Frequency % No. of H2RA reports Frequency % % Difference >1% Difference
United States 37,139 88.26 6,928 87.27 0.99
Great Britain 1122 2.67 177 2.23 0.44
Japan 472 1.12 382 4.81 3.69 *
Germany 357 0.85 24 0.30 0.55
France 330 0.78 29 0.37 0.42
Canada 309 0.73 22 0.28 0.46
Italy 312 0.74 39 0.49 0.25
Brazil 282 0.67 3 0.04 0.63
Turkey 173 0.41 13 0.16 0.25
Australia 151 0.36 7 0.09 0.27
China 149 0.35 9 0.11 0.24
Denmark 143 0.34 4 0.05 0.29
Spain 138 0.33 13 0.16 0.16
Nederlands 103 0.24 34 0.43 0.18
Sweden 52 0.12 6 0.08 0.05
Singapore 48 0.11 9 0.11 0.00
Belgium 41 0.10 9 0.11 0.02
New Zealand 42 0.10 3 0.04 0.06
Chile 28 0.07 3 0.04 0.03
India 15 0.04 15 0.19 0.15
Costa Rica 30 0.07 0 0.00 0.07
Unknown 198 0.47 45 0.57 0.10
Table 2. Frequency of PPI and H2RA “monotherapy” reports in FAERS by country of origin.
www.nature.com/scientificreports/
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Discussion
In this study, we quantified and confirmed the association between PPI exposure and the increased risk of AKI, 
CKD, ESRD, and electrolyte abnormalities by utilizing updated adverse event reports in the FAERS/AERS data-
base. Most interestingly, the extended set of reports revealed an association between PPI exposure and unex-
pected significant risk for nephrolithiasis and renal impairment (Fig. 1). For the first time there were sufficient 
records for analysis of the effects of individual PPIs and observed varying degrees of electrolyte and renal abnor-
malities (Figs 3 and 4).
Our analysis of renal adverse effects was in general agreement with previous studies that have documented an 
increased risk of incident AKI, incident CKD, CKD progression and ESRD in large observational cohorts. Klesper 
and colleagues performed a nested case-control study, including 184,480 patients, and found an increased risk of 
AKI with PPI prescription (OR 1.72, 95% confidence interval [CI] [1.27, 2.32], p < 0.001)22. In a population-based 
cohort study of 290,593 patients over the age of 65, Antoniou and colleagues confirmed the association of PPI 
use with AKI (hazard ratio [HR] 2.52, 95% CI [2.27, 2.79])29. In the Atherosclerosis Risk in Communities (ARIC) 
study Lazarus et al. performed a population based prospective cohort study with 10,482 patients and found an 
increased risk of incident AKI and CKD when comparing PPI users to H2RA users (HR, 1.58; 95% CI [1.05, 
2.04]) and (HR, 1.39; 95% CI [1.01, 1.91]), respectively)21. These population-based studies utilized ICD coding 
data to define the outcome of incident AKI and CKD. Xie and colleagues evaluated a prospective cohort includ-
ing 193,591 patients from the Veteran’s Affairs database and documented not only an increased risk of incident 
CKD (HR, 1.28; 95% CI [1.23, 1.34]) but also an increased risk for ESRD when comparing PPI users to H2RA 
users (HR, 1.96; 95% CI [1.21, 3.18])23 and in a later study demonstrated that CKD progression and ESRD can 
occur without intervening AKI28. The difference in values between different studies may be due to multiple fac-
tors including definitions of renal injury and the diagnostic criteria as well as the time dependent analyses using 
hazard ratios. The FAERS and AERS data derived frequencies are additionally influenced by the severity related 
threshold of the report submission. In summary we documented an OR of 4.2 for AKI with the lower 95% CI 
boundary of 2.9, OR values as large as 28.4, with the 95% CI between 12.7 and 63.5 for CKD and 35.5 with 95% CI 
between 5.0 and 250.0 for ESRD. Our results indicate significant increase in nephrolithiasis reports with (OR 2.8 
(95% CI [1.3, 6.0]). Nephrolithiasis finding is of particular interest since it has been associated with AKI, CKD, 
and ESRD progression but it only accounts for a small subset of renal injury cases30–32.
Hypomagnesemia was reported in the initial clinical trials and on the FDA package insert for every PPI as a 
rare side effect11. Accordingly, the frequency of hypomagnesemia reports for PPI patients is low, but the relative 
frequency was dramatically higher, almost eighty-fold, than for the H2RA control group. Secondly, detection bias 
may underestimate this adverse effect, since magnesium concentrations are not routinely measured compared to 
sodium, potassium and calcium. All five studied PPIs had comparable and increased ORs, with omeprazole show-
ing the largest magnitude. Omeprazole, being the first marketed and the first over-the-counter PPI, has been used 
for the longest time, therefore patients were likely to have longer drug exposure. It may be prudent to monitor 
magnesium levels in patients with ongoing PPI therapy and other risk factors for hypomagnesemia.
Previous studies examining the effect of PPIs’ on calcium levels were not consistent. Multiple small-scale 
studies have shown that PPIs decrease gastrointestinal calcium absorption33–35 and this deleterious effect is atten-
uated by administering acidic liquids36. However, other studies have noted that the change in gastric pH does not 
correlate with calcium levels37,38. In our analysis of 42,537 PPI and 8,309 H2RA cases, we found a clear increase 
in hypocalcemia in patients taking PPIs compared to patients receiving H2RAs. Although the mechanism for 
hypocalcemia is not clearly defined, we can conclude that all PPIs are significantly associated with hypocalcemia.
We evaluated alterations in serum potassium concentrations. The previous evidence for hypokalemia with 
PPI use was limited, mainly consisting of case reports39–41. We found that PPI utilization resulted in moderately 
increased hypokalemia, when compared to the H2RA cohort. As noted earlier, PPI utilization was correlated with 
CKD, known to cause fluctuations in electrolytes. While CKD can be associated with both hypokalemia (e.g. in 
the case of tubular dysfunction) and hyperkalemia42, we only observed a significant increase in hypokalemia. 
However, a small number of cases of hyperkalemia were reported out of 42,537 reports in FAERS/AERS. In con-
clusion, hypokalemia was more common than hyperkalemia in our analysis of patients receiving PPIs. Each PPI 
was shown to have increased odds of hypokalemia, except for rabeprazole which was not significant (OR 2.3 CI 
[0.27, 20]).
Hyponatremia has been reported as a rare post marketing adverse reaction in FDA package inserts for panto-
prazole, omeprazole, and esomeprazole11,43,44. In a retrospective study of 302 individuals receiving PPIs for longer 
than a year, Buon and colleagues found moderate hyponatremia in 18.7–46.3% of elderly patients45. It should 
Sex
PPI reports 
(n = 42,537)
Frequency 
(%)
H2RA reports 
(n = 8,309)
Frequency 
(%) P-value % Difference
Female 25,116 59.69 4,579 57.68 <0.001 2.01
Male 12,000 28.52 2,710 34.14 <0.001 5.62
Unreported 4,963 11.79 650 8.19 <0.001 3.61
Age difference
Mean age, years 
(SD) 58.3 (15.9) 55.6 (20.1) <0.001 2.7
Median age 58.6 59.7 <0.001 1.1
Unreported (%) 45.4 55.1
Table 3. Patient demographics in PPI and H2RA “monotherapy” cohorts.
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be noted that although dysnatremia is associated with CKD46, we observed only a minor yet significant increase 
in hyponatremia reports. Hypernatremia was not a significant adverse effect in PPI users. Our analysis showed 
hyponatremia effect to be most pronounced for omeprazole, followed by lansoprazole and rabeprazole.
The observed increased risks of renal and electrolyte adverse effects of PPIs warrant more careful considera-
tion in clinical practice. The risk-benefit ratio should be considered for the individual patient with respect to the 
adverse effects. When clinically indicated, PPIs should be used for the shortest duration necessary and chronic use 
is not recommended except for treatment of pathological hypersecretory conditions including Zollinger-Ellison 
syndrome and maintenance healing of erosive esophagitis11,43,44,47–54. It should be noted that the above-mentioned 
indications are FDA recommendations. Off-label and over-the-counter use of PPIs for the treatment of gastro-
esophageal reflux disorder (GERD) should be limited to four weeks11,43,44,52–54 but is often continued beyond the 
recommended limit. Continued use can result in rebound acid hypersecretion and hypergastrinemia after 4–8 
weeks of therapy55,56 leading to chronic use.
Conclusion
In our study we observed various levels of increased risk of renal and electrolyte ADRs in FAERS reports of 
individual PPI drugs with respect to H2RA reports. Regardless of which PPI is initiated, it may be benefi-
cial to follow dosing and duration recommendations established by the FDA11,43,44,52–54, American College of 
Gastroenterology47,48 and World Gastroenterology Organisation Global Guidelines49. It may be beneficial to mon-
itor renal function and electrolytes including potassium, calcium, magnesium, and sodium. Although H2RAs 
have not been shown to be as effective as PPIs, they might be considered as alternatives for patients who are at 
high risk for developing renal and electrolytes imbalances.
study Limitations
Since the FDA FAERS/AERS reporting is voluntary, only a subset of actual cases is represented, and ADR fre-
quencies do not represent the population incidences. A recent study found that FAERS/AERS reporting can 
be biased by legal and scientific variables and newsworthiness50. Another study has shown that FAERS/AERS 
reporting was significantly underreported for statins51. Some limitation stems from the absence of comprehen-
sive medical records. Although the indication section in the data set was used to exclude potential comorbidities, 
some concurrent medications and comorbidities may be missing from the records due to underreporting. This 
may have introduced noise into the cohort compositions, ADR frequencies and odds ratios. The mechanism 
of the adverse reaction cannot be derived from the FAERS/AERS records. The odds ratios represent frequency 
ratios of reported adverse effects between FAERS/AERS PPI and H2RA cohorts and are not based on population 
incidences. As with any association study, causality cannot be inferred from association. These cases were not 
clinically adjudicated for causality by experts.
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